Getting your player ready...
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer too. Two studies found it did not improve survival for most patients and kept their disease from worsening for only a few months, with more side effects.
The Genentech drug won approval in Europe last week for advanced ovarian cancer. But its maker has no immediate plans to seek the same approval in the United States.Denver Post staff and wire reports
